Get patients started +
Download the Patient Enrollment Form to order ZUSDURI and access support services for eligible patients
Get patients startedHow to bill ZUSDURI: permanent J-code J9282 and Medicare Part B ASP
ZUSDURI has a permanent J-code, J9282, effective January 1, 2026, and an established Average Sales Price (ASP) for Medicare Part B reimbursement. Established coding and payment pathways give practices fewer unknowns at claim submission.
Effective January 1, 2026, supporting standardized claims submission for ZUSDURI.
ZUSDURI has established an ASP for Medicare Part B reimbursement.
For Medicare claims using a permanent J-code, payment processing is generally observed in approximately 14 to 21 days on average.
Recent internal ZUSDURI reimbursement experience has been directionally consistent with this range.
Actual timing may vary by claim, payer, site of care, documentation, and other factors. Coverage and reimbursement are not guaranteed.
Affordability support
- Eligible commercially insured patients may pay as little as $50 per dose, with additional support options based on coverage
- Patient assistance and independent charitable foundation support may also be available for eligible patients
Coverage, payment, and practice support in one place
Find the tools your practice needs to understand ZUSDURI coverage, bill appropriately, manage product access, and reduce access barriers and reimbursement friction.
Is ZUSDURI covered?
96%open access for ZUSDURI, with99.8%of benefit requests approved across major plan types
Explore coverage resources
How is ZUSDURI billed?
Permanent J-code J9282, established ASP for Medicare Part B reimbursement, and observed payment-processing context
View billing information
Practice support
Return goods support, UroGen Support, billing and coding tools, and specialty pharmacy fulfillment resources
Explore practice resourcesReturn goods support to reduce financial and operational disruption
If an eligible dose is unused due to reconstitution error, missed appointment, or delivery issue, UroGen’s flexible Return Goods Policy may reduce unused-dose disruption for the practice.
Approved replacement dose support
Approved ZUSDURI replacement doses are typically delivered in 3 to 5 business days, subject to eligibility rules.
Tools to reduce reimbursement barriers: ZUSDURI prior authorization, appeals, claims resources, and more
Use these resources to check coverage requirements, prepare prior authorization and medical necessity documentation, submit claims, manage product access, address patient affordability, and handle treatment disruptions.
Check ZUSDURI prior authorization requirements
Submit clean ZUSDURI claims
Understand ZUSDURI coding and payment
Order ZUSDURI: choose a fulfillment pathway
Handle treatment disruptions
Get patients started
Need help with ZUSDURI access,
ordering, or reimbursement?
For help with ordering or reimbursement, visit UROGENSUPPORT.com or contact UroGen Support at 833-UROGEN1 (833-876-4361).
Indications and Usage
ZUSDURI® is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
IMPORTANT SAFETY INFORMATION
Contraindications
ZUSDURI is contraindicated in patients with perforation of the bladder or in patients with prior hypersensitivity reactions to mitomycin or any component of the product.
Warnings and Precautions
Risks in Patients with Perforated Bladder
ZUSDURI may lead to systemic exposure to mitomycin and severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised. Evaluate the bladder before the intravesical instillation of ZUSDURI and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.
Embryo-Fetal Toxicity
Based on findings in animals and mechanism of action, ZUSDURI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with ZUSDURI and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZUSDURI and for 3 months following the last dose.
Adverse Reactions
Common Adverse Reactions
The most common (≥10%) adverse reactions, including laboratory abnormalities, that occurred in patients treated with ZUSDURI were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.
Additional Adverse Reactions Information
Clinically relevant adverse reactions occurring in <10% of patients who received ZUSDURI included increased urinary frequency, fatigue, urinary incontinence, urinary retention, urethral stenosis, genital pain, urinary urgency, genital edema, genital pruritus, genital rash, urethritis, acute kidney injury, balanoposthitis, and nocturia.
Use in Specific Populations
Lactation
Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ZUSDURI and for 1 week following the last dose.
Preparation and Administration Information
ZUSDURI is to be administered by intravesical instillation only. Do not administer ZUSDURI by pyelocalyceal instillation or by any other route.
ZUSDURI must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the ZUSDURI Instructions for Pharmacy and administration instructions found in the ZUSDURI Instructions for Administration.
ZUSDURI may discolor urine to a violet to blue color following the instillation procedure. Advise patients for at least 24 hours post-instillation to avoid urine contact with skin, to void urine sitting on a toilet, and to flush the toilet several times after use. Advise patients to wash hands, perineum or glans with soap and water after each instillation procedure.
ZUSDURI is a hazardous drug. Follow applicable special handling and disposal procedures.
Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.